The Impact of a Recently Approved Automated Insulin Delivery System on Glycemic, Sleep, and Psychosocial Outcomes in Older Adults With Type 1 Diabetes: A Pilot Study. (May 2022)
- Record Type:
- Journal Article
- Title:
- The Impact of a Recently Approved Automated Insulin Delivery System on Glycemic, Sleep, and Psychosocial Outcomes in Older Adults With Type 1 Diabetes: A Pilot Study. (May 2022)
- Main Title:
- The Impact of a Recently Approved Automated Insulin Delivery System on Glycemic, Sleep, and Psychosocial Outcomes in Older Adults With Type 1 Diabetes: A Pilot Study
- Authors:
- Bisio, Alessandro
Gonder-Frederick, Linda
McFadden, Ryan
Cherñavvsky, Daniel
Voelmle, Mary
Pajewski, Michael
Yu, Pearl
Bonner, Heather
Brown, Sue A. - Abstract:
- Background: Older adults with type 1 diabetes (≥65 years) are often under-represented in clinical trials of automated insulin delivery (AID) systems. We sought to test the efficacy of a recently FDA-approved AID system in this population. Methods: Participants with type 1 diabetes used sensor-augmented pump (SAP) therapy for four weeks and then used an AID system (Control-IQ) for four weeks. In addition to glucose control variables, patient-reported outcomes (PRO) were assessed with questionnaires and sleep parameters were assessed by actigraphy. Results: Fifteen older adults (mean age 68.7 ± 3.3, HbA1c of 7.0 ± 0.8) completed the pilot trial. Glycemic outcomes improved during AID compared to SAP. During AID use, mean glucose was 146.0 mg/dL; mean percent time in range (TIR, 70-180 mg/dL) was 79.6%; median time below 70 mg/dL was 1.1%. The AID system was in use 92.6% ± 7.0% of the time. Compared to SAP, while participants were on AID the TIR increased significantly (+10%, P = .002) accompanied by a reduction in both time above 180 mg/dL (−6.9%, P = .005) and below 70 mg/dl (−0.4%, P = .053). Diabetes-related distress decreased significantly while using AID ( P = .028), but sleep parameters remained unchanged. Conclusions: Use of this AID system in older adults improved glycemic control with high scores in ease of use, trust, and usability. Participants reported an improvement in diabetes distress with AID use. There were no significant changes in sleep.
- Is Part Of:
- Journal of diabetes science and technology. Volume 16:Number 3(2022)
- Journal:
- Journal of diabetes science and technology
- Issue:
- Volume 16:Number 3(2022)
- Issue Display:
- Volume 16, Issue 3 (2022)
- Year:
- 2022
- Volume:
- 16
- Issue:
- 3
- Issue Sort Value:
- 2022-0016-0003-0000
- Page Start:
- 663
- Page End:
- 669
- Publication Date:
- 2022-05
- Subjects:
- artificial pancreas -- automated insulin delivery -- closed-loop control -- continuous glucose monitoring -- continuous subcutaneous insulin infusion -- sensor-augmented pump therapy
Diabetes -- Periodicals
Medical technology -- Periodicals
Diabetes Mellitus -- Periodicals
616.462005 - Journal URLs:
- http://ejournals.ebsco.com/direct.asp?JournalID=712321 ↗
http://www.jodsat.org/about.html ↗
http://online.sagepub.com/ ↗ - DOI:
- 10.1177/1932296820986879 ↗
- Languages:
- English
- ISSNs:
- 1932-2968
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20910.xml